zheshang: Continuous realization of technological innovation upgrade driving the continuous improvement of performance expectations for innovative drugs and industry chain.

The commercialization period of innovative drugs in the industry chain, driven purely by incremental value, is entering the phase of realization. The scarce incremental prosperity of the pharmaceutical sector continues to rise, with increasing international competitiveness, and there is still room for upward valuation.

Zhitong FinanceOct 29 22:28 ET

The Five-year Underlying Earnings Growth at 3SBio (HKG:1530) Is Promising, but the Shareholders Are Still in the Red Over That Time

Simply Wall StOct 29 18:58 ET

Hong Kong healthcare stocks receive attention from investors again, with Trifolium Biotech surging nearly 15%.

①What is the impact of medical insurance negotiations on pharmaceutical stocks? ②What are the reasons for the rise of Tri Clover Biopharmaceutical and Yimington Corporation?

cls.cnOct 28 23:05 ET

3SBio Arm to Obtain Commercialization Rights for RMX Biopharma's Paclitaxel Oral Solution

MT NewswiresOct 24 07:26 ET

3SBio Secures Exclusive Rights for Cancer Drug

TipRanksOct 24 05:38 ET

3sbio (01530.HK): Shenyang 3sbio and Haihe Pharmaceutical reached a cooperation agreement on paclitaxel oral solution.

Galunhui October 24th | 3sbio (01530.HK) announced that its subsidiary Shenyang 3sbio Pharmaceutical Co., Ltd. ("Shenyang 3sbio") reached an exclusive commercialization cooperation agreement for oral paclitaxel solution with Shanghai Haihe Pharmaceutical Research and Development Co., Ltd. ("Haihe Pharmaceutical") and its subsidiary Numel Xi (Shanghai) Medical Technology Co., Ltd. ("Numel Xi Medical"). According to the agreement, Shenyang 3sbio will obtain the exclusive commercialization rights for oral paclitaxel solution under the territory of mainland China and Hong Kong of China from Numel Xi Medical. Shenyang 3sbio will pay Numel Xi Medical in accordance with the agreement.

Gelonghui FinanceOct 24 05:28 ET